Ablynx, Eddingpharm Ink Chinese Pact on RANK Ligand Inhibitor
Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving €2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST